β-blockers remain the basic drugs for the treatment of coronary heart disease (CHD). For many years, they have been used to treat patients with stable angina (SA), unstable angina (UA), and myocardial infarction (MI). The mechanism of antianginal action of these drugs is associated with a decrease in heart rate, myocardial contractility and a decrease in systolic blood pressure. The increase in the coronary blood flow is explained by the prolongation of the period of diastolic filling of the ventricles of heart and the decrease in vasoconstriction of the coronary arteries during exercise. β-blockers are recognized as antianginal drugs of the first choice. However, formally, there is no evidence of their beneficial effect on the survival of patients with SA. The prognostic effect of β-blockers has been proven only in patients who have suffered from MI or UA, i.e., in the implementation of secondary prevention of acute coronary syndrome. One of the reasons for extrapolating these data to the recommendations for primary prevention was the proven
Influence of bisoprolol and nebivolol on the spectrum of substituted amino acids in blood plasma of patients...

ability of β-blockers to reduce the number of episodes of painless myocardial ischemia, according to Holter ECG monitoring [1, 2].

In addition to the already known mechanisms of action of β-blockers, it is worth noting the property of nebivolol to promote the release of nitric oxide (NO), which is one of the most important mediators functionally involved in various biological processes [3—6].

In previous studies, we obtained data on the violation of the amino acid spectrum of blood plasma in patients with emergencies [7, 8]. It is advisable to study the effect of bisoprolol and nebivolol on the spectrum of plasma amino acids in patients with SA.

We examined 75 patients with emergencies aged 65 to 76 years (mean age of patients — 68.2 years ± 6.3 years). Patients were divided into two groups: I — 37 persons who received cardiet, bisoprolol, atoris, enap, acetylsalicylic acid, clopidogrel; II — 38 persons whose therapy, in addition to these drugs, included L-arginine (100 ml intravenously for 10 days). All groups of patients were statistically homogeneous and comparable. The study did not include patients with heart failure stage IIB and III, atrial fibrillation, comorbidities in the stage of decompensation, cancer, and diseases of the musculoskeletal system.

Serum amino acids (AA) were used as the object of the study. The method of ion exchange liquid column chromatography was used. The following AA substitutes were determined in blood serum: ornithine, taurine, aspartic acid, serine, glutamic acid, proline, glycine, alanine, cysteine, tyrosine, and glutamine. The results of the research were processed on a personal computer using the Microsoft Office software package. For the statistical processing of the obtained data, Microsoft Excel 2010 was used. The significance of the difference between the average values of the indicators of different groups was determined by the definition of Student’s t-test or Pearson’s test.

73 patients aged 58 to 75 years (mean age — 67.2 years ± 5.2 years) with SA were divided into two groups: During the day in basic therapy, group I (38 patients) received bisoprolol, enalapril, atorvastatin, acetylsalicylic acid, and isosorbide dinitrate, group II (35 patients) received nebivolol, enalapril, rosuvastatin, acetylsalicylic acid, and isosorbide dinitrate. Examination of patients was performed at the beginning of the treatment and after 20 days. The control group (CG) included 18 healthy people aged 49—58 years (mean age — 53.4 years ± 4.7 years). In patients taking nebivolol, compared with patients treated with bisoprolol, the level of total AA increased significantly by 31.29 μmol/100 ml, the amount of nonessential AA — by 22.22 μmol/100 ml, the amount of irreplaceable AA — by 9.13 μmol/100 ml, although, in both groups of patients, these indicators remained significantly lower compared to CG. It should be noted that against the background of therapy with nebivolol did not change the level of AA with a branched side chain compared to pre-treatment, and with bisoprolol the amount of these AA decreased even more compared to CG by 31.99 μmol/100 ml and with an indicator before treatment — by 9.66 μmol/100 ml (Table 1).

The analysis of the results showed that, against the background of treatment in patients of both groups, there was a significant decrease in arginine levels compared to pre-treatment — by 4.18 and 1.97 μmol/100 ml. Compared with CG, the level of AA in patients receiving bisoprolol decreased by 6.03 μmol/100 ml, and in patients receiving nebivolol — by 3.82 μmol/100 ml (Table 2).

It is noteworthy that in patients of the two studied groups against the background of treatment significantly decreased the level of ornithine in plasma compared with pre-treatment —
by 2.48 and 1.23 μmol/100 ml. Compared with CG in patients receiving nebivolol, ornithine levels returned to normal. It should be noted that, in patients with SA whose therapy included nebivolol, significantly increased the level of taurine in plasma compared with pre-treatment by 2.78 μmol/100 ml, while in patients whose therapy included bisoprolol, the level of this AA did not change significantly.

After treatment, patients receiving nebivolol, in contrast to patients receiving bisoprolol, significantly increased the plasma serine levels by 3.0 μmol/100 ml, glutamic acid — by 2.49 μmol/100 ml. Significantly, in patients with SA receiving bisoprolol and nebivolol, the level of cysteine in the blood plasma was significantly reduced compared to treatment — by 3.4 and 3.2 μmol/100 ml. But in patients receiving nebivolol, the level of this AA compared with CG was normalized.

**Table 1. The effect of bisoprolol and nebivolol on the amino acid spectrum of blood plasma in patients with SA, μmol/100 ml (M ± m)**

| Indicator                          | CG (n = 8)          | Before treatment (n = 73) | On treatment          |
|-----------------------------------|---------------------|--------------------------|-----------------------|
| General amount of AA              | 352.45 ± 10.40      | 236.6 ± 6.7              | 172.11 ± 7.50         |
| Nonessential AA                   | 275.96 ± 8.80       | 152.62 ± 6.50            | 110.04 ± 5.60         |
| Sulfur-containing AA              | 19.43 ± 2.10        | 14.37 ± 0.90             | 10.44 ± 1.20          |
| AA with a branched chain          | 50.62 ± 3.50        | 28.28 ± 1.60             | 18.63 ±1.50           |

*Significant difference in relation to the control group. 
#Significant difference in terms of indicators for treatment. 
&A significant difference between groups of patients.

**Table 2. The effect of bisoprolol and nebivolol on the spectrum of replacement amino acids in the blood plasma of patients with SA, μmol/100 ml (M ± m)**

| Indicator     | CG (n = 18) | Before treatment (n = 73) | On treatment          |
|---------------|-------------|--------------------------|-----------------------|
| Ornithine     | 14.36 ± 1.20| 15.09 ± 1.10             | 12.61 ± 1.30          |
| Taurine       | 9.02 ± 0.44 | 3.44 ± 0.06              | 3.88 ± 0.07           |
| Aspartic acid | 2.12 ± 0.06 | 2.79 ± 0.05              | 2.61 ± 0.05           |
| Serin         | 18.75 ± 1.43| 11.5 ± 0.9               | 11.89 ± 0.60          |
| Glutamic acid | 22.64 ± 1.16| 12.25 ± 0.08             | 13.53 ± 0.70          |
| Proline       | 21.42 ± 1.27| 10.94 ± 0.09             | 9.11 ± 0.75           |
| Glycine       | 31.84 ± 2.24| 26.58 ± 0.70             | 20.48 ± 1.55          |
| Alanine       | 46.53 ± 1.31| 42.78 ± 1.30             | 31.01 ± 1.24          |
| Cysteine      | 6.82 ± 0.31 | 8.32 ± 0.06              | 4.92 ± 0.05           |
| Tyrosine      | 6.32 ± 0.08 | 6.72 ± 0.07              | 4.35 ± 0.09           |
| Glutamine     | 51.89 ± 2.45 | 12.21 ± 0.70           | 4.58 ± 0.05           |

*Significant difference in relation to the control group. 
#Significant difference in terms of indicators for treatment. 
&A significant difference between groups of patients.
The level of tyrosine in patients receiving bisoprolol was significantly reduced compared with CG by 1.97 μmol/100 ml, and with the pre-treatment index by 2.37 μmol/100 ml. In patients treated with nebivolol, the tyrosine levels did not change significantly from CG and pre-treatment. Significantly, patients in both groups significantly decreased plasma ammonia levels after treatment — by 6.37 and 15.77 μmol/100 ml, respectively. Against the background of nebivolol treatment revealed a more significant decrease in plasma ammonia, which, of course, is a positive factor in this category of patients.

Conclusions.

1. In patients with SS against the background of antianginal therapy, which included bisoprolol and nebivolol, there was a significant decrease in the total amount of AA, the amount of nonessential AA and the amount of essential AA compared with pre-treatment and CG, however, in patients receiving nebivolol, the catabolism occurs slower, as evidenced by a significant difference between these indicators between the two groups of patients after treatment.

2. Against the background of nebivolol treatment, there is a positive dynamics of sulfur-containing AA levels: methionine levels were maintained, taurine levels were significantly increased, and cystine levels were normalized, which indirectly indicates the cardioprotective and antiprotective effects of nebivolol.

3. Against the background of antianginal therapy with nebivolol, there is significantly less use of arginine than in patients receiving bisoprolol, which indicates the activation of compensation processes.

4. Nebivolol normalized the level of isoleucine, which is a part of the tricarboxylic acid cycle and promotes mitochondrial biogenesis in myocardium and other muscles, preventing the oxidative stress.

5. In patients with SA receiving antianginal therapy with the inclusion of nebivolol, against the background of the normalization of ornithine, a significant decrease in the ammonia levels was observed compared with those in patients receiving bisoprolol.

REFERENCES

1. Vinereanu, D., Gherghinescu, C., Ciobanu, A. O., Magda, S., Niculescu, N., Dulgheru, R., Dragoi, R., Lautaru, A., Cinteza, M. & Fraser, A. G. (2011). Reversal of subclinical left ventricular dysfunction by antihypertensive treatment: a prospective trial of nebivolol against metoprolol. J. Hypertens., 29, No. 4, pp. 809-817. https://doi.org/10.1097/HJH.0b013e3283442f37

2. Waehre, T., Halvorsen, B., Damás, J. K., Yndestad, A., Brosstad, E., Gullestad, L., Kjekshus, J., Frøland, S. S. & Aukrust, P. (2002). Inflammatory imbalance between IL-10 and TNFalpha in unstable angina potential plaque stabilizing effects of IL-10. Eur. J. Clin. Invest., 32, pp. 803-810. https://doi.org/10.1046/j.1365-2362.2002.01069.x

3. Girin, V. V. (2009). Assessment of the pathological condition in type 1 diabetes by determining the fatty acid spectrum of salivary lipids. Nauk. visnyk Nats. med. un-tu im. O.O. Bohomoltsia, No. 2/3, pp. 93-96 (in Ukrainian).

4. Lutai, M. I., Bugayenko, V. V., Moiseyenko, O. I., Mushtenko, L. O. & Slobodskyi, V. A. (2011). The value of L-arginine in the treatment of patients with cardiovascular pathology. Ukr. cardiol. zhurn., No. 4, p. 96-107 (in Ukrainian).

5. Athyros, V. G., Kakafika, A. I., Tziomalos, K., Karagiannis, A. & Mikhailidis, D. P. (2009). Pleiotropic effects of statins — clinical evidence. Curr. Pharm. Des., 15, No. 5, pp. 479-489. https://doi.org/10.2174/13816120978315729
ВПЛИВ БІСОПРОЛОЛУ ТА НЕБІВОЛОЛУ НА СПЕКТР ЗАМІННИХ АМІНОКИСЛОТ ПЛАЗМИ КРОВІ У ХВОРИХ НА СТАБІЛЬНУ СТЕНОКАРДІЮ

Впродовж багатьох років β-адреноблокатори застосовують для лікування хворих на ішемічну хворобу серця. У хворих на стабільну стенокардію вивчено вплив β-адреноблокаторів на амінокислотний спектр сироватки крові, порушення якого розглядається як одна з патогенетичних ланок розвитку атеросклерозу.

Встановлено ефективніший вплив небівололу порівняно з бісопрололом на дисбаланс амінокислот. У хворих на стабільну стенокардію на фоні антиангінальної терапії, що включала бісопролол і небіволол, відмічене достовірне зменшення загальної суми амінокислот, суми замінних амінокислот та суми незамінних амінокислот порівняно з показниками до лікування. На фоні лікування небівололом спостерігалася по-зитивна динаміка рівня сірковмісних амінокислот (утримався рівень метіоніну, достовірно збільшився рівень таурину, нормалізувався рівень цистеїну), нормалізувався рівень ізолейцину, що опосередковано свідчить про кардіопротекторну та антіпротекторну дію небівололу.

Ключові слова: β-адреноблокатори, бісопролол, небіволол, амінокислоти.